- Syneos Health ( NASDAQ: SYNH ) said it expanded its partnership with Datavant to accelerate delivery of new therapies to patients.
- Syneos will use Datavant Switchboard to develop advanced analytics and AI-driven technologies to execute more efficient clinical trials, the companies said in an Oct. 11 press release.
- The collaboration will use the full suite of capabilities in Datavant Switchboard and data ecosystem to accelerate clinical development and commercialization of new therapies, Syneos added.
For further details see:
Syneos, Datavant expand partnership on data analytics for clinical trials